The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.

Richardson, Kelden; Keam, Simon P; Zhu, Joe Jiang; Meyran, Deborah; D'Souza, Criselle; Macdonald, Sean; Campbell, Kerry; Robbins, Michael; Bezman, Natalie A; Todd, Kirsten; Quach, Hang; Ritchie, David S; Harrison, Simon J; Prince, H Miles; Trapani, Joseph A; Jenkins, Misty R; Beavis, Paul A; Darcy, Phillip K; Neeson, Paul J

Richardson, Kelden; Keam, Simon P; Zhu, Joe Jiang; Meyran, Deborah; D'Souza, Criselle; Macdonald, Sean; Campbell, Kerry; Robbins, Michael; Bezman, Natalie A; Todd, Kirsten; Quach, Hang; Ritchie, David S; Harrison, Simon J; Prince, H Miles; Trapani, Joseph A; Jenkins, Misty R; Beavis, Paul A; Darcy, Phillip K; Neeson, Paul J.

Affiliation

Richardson K; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
Keam SP; Tumor Suppression and Cancer Sex Disparity Lab, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
Zhu JJ; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
Meyran D; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
D'Souza C; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
Macdonald S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
Campbell K; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111.
Robbins M; Translational Medicine, Bristol-Myers Squibb, Cambridge, MA, USA, (current: io904 LLC).
Bezman NA; Oncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA.
Todd K; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
Quach H; Department of Haematology, St Vincent's Hospital, Melbourne, Australia; Faculty of Medicine, The University of Melbourne.
Ritchie DS; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
Harrison SJ; Faculty of Medicine, The University of Melbourne, Australia; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
Prince HM; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Faculty of Medicine, The University of Melbourne, Australia; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
Jenkins MR; Faculty of Medicine, The University of Melbourne, Australia; Immunology Division, Walter and Eliza Hall Institute, Melbourne, Australia; Institute for Molecular Science, La Trobe University, Bundoora.
Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
Darcy PK; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
Neeson PJ; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne. Paul.neeson@petermac.org.

Haematologica ; 108(1): 83-97, 2023 01 01.

Article de En | MEDLINE | ID: mdl-35770527

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Myélome multiple Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Haematologica Année: 2023 Type de document: Article Pays de publication: Italie

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google